このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Prospective Multicentre Validation of a Landmark Machine Learning Model for ICU Mortality in Neurocritical Care (LANDMARK-ICU)

2026年11月11日 更新者:Han Chen、Fujian Provincial Hospital

A Prospective Multicentre Observational Study Validating a Landmark-Based Machine Learning Model for Dynamic Prediction of Mortality in Patients Receiving Continuous Intracranial Pressure Monitoring

Mortality prediction in neurocritical care relies on scores computed at admission, which cannot update as the clinical course evolves. We previously developed a landmark-based machine learning model that converts hourly physiological data, including intracranial pressure, into an updating risk of death. The model was developed in a large public database and validated retrospectively in a second, independent one. This prospective multicentre study will test the model in consecutive patients at participating hospitals in Fujian Province, China. Physiological data will be collected as part of routine care. The model will generate risk estimates that are recorded for analysis but not shown to treating clinicians, and no treatment decision will be influenced by the study. The primary analysis will assess discrimination and calibration of the model for death during the intensive care stay. Secondary analyses will compare the model with severity scores in routine use and examine performance by aetiology.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

Model development used the Medical Information Mart for Intensive Care IV database and external validation used the eICU Collaborative Research Database. Both analyses were retrospective and are not part of this registration. This registration covers the prospective multicentre validation only. Inclusion requires age 18 years or older, continuous intracranial pressure monitoring for at least 24 hours, and a diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage. The model uses seven hourly physiological channels with observation masks and elapsed-time features. The primary endpoint is death during the intensive care stay; 28-day mortality, length of stay and Glasgow Outcome Scale at 6 months are secondary. The sample size of 100 patients follows the approved protocol, which assumed area under the curve 0.80 with alpha 0.05 and beta 0.20.

研究の種類

観察的

入学 (推定)

100

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Fujian
      • Fuzhou、Fujian、中国
        • Fujian Provincial Hospital
      • Fuzhou、Fujian、中国
        • First Affiliated Hospital of Fujian Medical University
      • Quanzhou、Fujian、中国
        • Hui'an County Hospital
      • Quanzhou、Fujian、中国
        • Second Affiliated Hospital of Fujian Medical University
      • Quanzhou、Fujian、中国
        • Shishi City Hospital
      • Zhangzhou、Fujian、中国
        • Zhangzhou Municipal Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~90年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

Adults in intensive care units of participating hospitals who require continuous intracranial pressure monitoring after acute brain injury.

説明

Inclusion Criteria:

  • Age 18 years or older
  • Continuous intracranial pressure monitoring for at least 24 hours
  • Diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage
  • Written informed consent from the patient or a legal representative

Exclusion Criteria:

  • Incomplete or unusable intracranial pressure recordings
  • Loss to follow-up or unavailable outcome information
  • Pre-existing severe neurological disease that would confound assessment

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Neurocritical care cohort

Consecutive patients receiving continuous intracranial pressure monitoring, contributing to the risk set at each landmark.

Observational application of a fixed prediction model to hourly physiological data; no treatment is assigned or withheld.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 24-hour landmark
時間枠:24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Discrimination of the locked landmark model, quantified as the area under the receiver operating characteristic curve, where 0.5 indicates no discrimination and 1.0 perfect discrimination. Death is ascertained from the medical record and the curve is estimated with a 95% confidence interval

24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

二次結果の測定

結果測定
メジャーの説明
時間枠
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 48-hour and 72-hour landmarks
時間枠:48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Same measurement as the primary outcome, estimated separately at the 48-hour and 72-hour landmarks with 95% confidence intervals

48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
Calibration slope (dimensionless) of the landmark model at the 24-, 48- and 72-hour landmarks
時間枠:24, 48 and 72 hours after intensive care admission

Slope obtained by logistic regression of the observed outcome on the logit of the predicted risk; a value of 1 indicates perfect calibration, below 1 indicates over-fitting and above 1 under-fitting.

24, 48 and 72 hours after intensive care admission
Brier score (range 0 to 1) of the landmark model at the 24-, 48- and 72-hour landmarks
時間枠:24, 48 and 72 hours after intensive care admission

Mean squared difference between predicted risk and observed outcome, where lower values indicate better overall performance.

24, 48 and 72 hours after intensive care admission
Difference in area under the receiver operating characteristic curve (range -1 to 1) between the landmark model and the centre-recorded APACHE II score
時間枠:24, 48 and 72 hours after intensive care admission

Paired difference in discrimination, computed as model area under the curve minus APACHE II area under the curve on the same patients, with 95% confidence interval; negative values indicate the model discriminates worse than APACHE II

24, 48 and 72 hours after intensive care admission
Net benefit (dimensionless) of the landmark model from decision-curve analysis at the 24-hour landmark
時間枠:24 hours after intensive care admission

Net benefit computed across threshold probabilities from 0.05 to 0.50, compared with the strategies of treating all patients and treating none

24 hours after intensive care admission
Area under the receiver operating characteristic curve (range 0 to 1) by primary diagnosis at the 24-, 48- and 72-hour landmarks
時間枠:24, 48 and 72 hours after intensive care admission

Discrimination estimated separately for traumatic brain injury, aneurysmal subarachnoid haemorrhage and intracerebral haemorrhage, reported descriptively because stratum sizes are expected to be small

24, 48 and 72 hours after intensive care admission
28-day all-cause mortality, as specified in the approved protocol
時間枠:28 days after intensive care admission
28 days after intensive care admission
Length of intensive care stay
時間枠:From intensive care admission to intensive care unit discharge, up to 28 days

Duration of intensive care stay in days, right-censored at day 28 for patients still in intensive care

From intensive care admission to intensive care unit discharge, up to 28 days
Glasgow Outcome Scale score (range 1 to 5, higher is better) at 6 months
時間枠:6 months after intensive care admission

Glasgow Outcome Scale, an ordinal scale from 1 (death) to 5 (good recovery), with higher scores indicating better outcome; assessed by telephone or outpatient follow-up

6 months after intensive care admission

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Han Chen, MD、Fujian Provincial Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2027年12月12日

研究の完了 (推定)

2028年1月1日

試験登録日

最初に提出

2026年11月7日

QC基準を満たした最初の提出物

2026年11月11日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • FJPH-ICP-01

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

De-identified individual participant data will not be shared publicly because small centre volumes could permit re-identification. The model specification, analysis code and summary results will be published.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。